These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17613342)

  • 1. Adverse event reporting.
    Kruft B; Nelson LA; Stewart JA; Stewart WC
    Ophthalmology; 2007 Jul; 114(7):1420. PubMed ID: 17613342
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious adverse event reporting.
    Stewart WC; Stewart JA; Demos CM; Turner M
    Ophthalmology; 2009 Dec; 116(12):2485-2485.e1. PubMed ID: 19948292
    [No Abstract]   [Full Text] [Related]  

  • 4. New software to facilitate clinical trials safety reporting.
    J Support Oncol; 2004; 2(5):432-3. PubMed ID: 15524072
    [No Abstract]   [Full Text] [Related]  

  • 5. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.
    Borja-Hart NL; Benavides S; Christensen C
    Ann Pharmacother; 2009 Feb; 43(2):356-9. PubMed ID: 19155346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four initiatives proposed to improve safety reporting in clinical trials.
    J Support Oncol; 2004; 2(5):431-2. PubMed ID: 15524071
    [No Abstract]   [Full Text] [Related]  

  • 7. Some concerns about adverse event reporting in randomized clinical trials.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(2):143-5. PubMed ID: 18537786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials?
    Bruner DW
    J Clin Oncol; 2007 Dec; 25(34):5345-7. PubMed ID: 18048812
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety reporting in randomized clinical trials - a need for improvement.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(2):209-10. PubMed ID: 19583556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for monitoring and documenting adverse drug reactions.
    Venulet J; ten Ham M
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):112-29. PubMed ID: 8705089
    [No Abstract]   [Full Text] [Related]  

  • 12. Poor reporting of adverse effects in clinical trials: in urology too.
    Prescrire Int; 2011; 20(118):184. PubMed ID: 21751754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More thoughts on the reporting of adverse events in cancer clinical trials.
    Extermann M
    J Clin Oncol; 2007 Mar; 25(7):918; author reply 918-9. PubMed ID: 17327621
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of calcium antagonists--a question for the SBU].
    Philip-Shansky A; Higham P
    Lakartidningen; 1995 Nov; 92(44):4076. PubMed ID: 8538266
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation and registration of adverse events in clinical drug trials in migraine.
    Tfelt-Hansen P; Bjarnason NH; Dahlöf C; Derry S; Loder E; Massiou H;
    Cephalalgia; 2008 Jul; 28(7):683-8. PubMed ID: 18498392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance--a commitment of medical professional.
    Daga S
    J Indian Med Assoc; 2008 Dec; 106(12):775. PubMed ID: 19370945
    [No Abstract]   [Full Text] [Related]  

  • 17. Lessons from clinical research: adverse events or complications?
    McLaughlin JF
    Dev Med Child Neurol; 1996 Jul; 38(7):565-6. PubMed ID: 8674906
    [No Abstract]   [Full Text] [Related]  

  • 18. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions reporting by physicians in Ibadan, Nigeria.
    Okezie EO; Olufunmilayo F
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):517-22. PubMed ID: 18404621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007 [Vaccine 2009;27:290-297].
    Niu M; Ball R
    Vaccine; 2009 Nov; 27(48):6654-5. PubMed ID: 19716457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.